Stephen Lam Chan, MD - Recalibrating Survival: Available and Recently Approved Immunotherapy-Based Combination Approaches in Unresectable HCC

Please visit answersincme.com/TZQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in clinical oncology discusses optimizing patient outcomes with immunotherapy-based combination approaches in unresectable hepatocellular carcinoma (HCC). Upon completion of this activity, participants should be better able to: Recognize the role of available and recently approved immunotherapy-based combination regimens for the management of unresectable HCC; Outline the practical implications of the clinical trial data evaluating available and recently approved immunotherapy-based combination regimens for unresectable HCC; and Review a personalized approach to optimize patient outcomes on available and recently approved immunotherapy-based combination regimens, thus enhancing quality of life.

There are no comments yet.

Please log in to write the first comment.